Research Articles – Page 7

Research Article

Efficacy and safety of subcutaneous efgartigimod with prednisone in moderate-to-severe pemphigus (ADDRESS): a global, phase III, randomised controlled, double-blind trial.

Subcutaneous Efgartigimod Fails to Improve Remission Rates Over Corticosteroids Alone in Pemphigus — In a phase III randomised controlled trial, subcutaneous efgartigimod PH20 added to prednisone did not significantly increase the rate of complete remission on minimal therapy compared with prednisone alone in moderate-to-severe pemphigus vulgaris (35.5% vs. 30.3%; OR 1.19, 95% CI 0.60–2.41; P=0.60).

Sep 11, 2026 · Br J Dermatol · Immunology

90

Clinical Trial

Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.

Osimertinib Plus Chemotherapy Nearly Doubles Progression-Free Survival in TP53-Mutated EGFR-Positive NSCLC — In treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer who also harbored concurrent TP53 mutations, adding chemotherapy to osimertinib more than doubled median progression-free survival compared with osimertinib alone — 34.0 months versus 15.6 months — representing roughly a 56% reduction in the risk of disease progression or death (HR 0.44, 95% CI 0.32–0.60; P < .001).

Sep 8, 2026 · JAMA · Neurology

81

Research Article

Impact of Shexiang Baoxin Pill (MUSKARDIA) on Cardiovascular Outcomes by Baseline Hemoglobin Levels in 2,494 Patients with Chronic Stable Coronary Artery Disease: A Secondary Subgroup Analysis.

MUSKARDIA Cuts MACE Risk by Half in CAD Patients with Lower Hemoglobin — In CAD patients with baseline hemoglobin below 140 g/L, MUSKARDIA (Shexiang Baoxin Pill) was associated with roughly half the risk of major adverse cardiovascular events compared to placebo — about 55% lower risk (HR 0.45, 95% CI 0.21–0.96, P=0.038) — along with a 68% reduction in non-fatal myocardial infarction.

Sep 12, 2026 · Chin J Integr Med · Neurology

85

Clinical Trial

Safety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial.

Oral Alixorexton Produces Large Wakefulness Gains in Narcolepsy Type 1 Phase 2 Trial — Once-daily oral alixorexton, a selective orexin 2 receptor agonist, produced placebo-corrected improvements in mean sleep latency on the Maintenance of Wakefulness Test of 22.2 minutes (95% CI 17.2–27.2) at the 4 mg dose, 24.1 minutes (95% CI 19.0–29.1) at 6 mg, and 26.0 minutes (95% CI 21.0–31.0) at 8 mg after six weeks of treatment in adults with narcolepsy type 1.

Aug 24, 2026 · Lancet Neurol · Neurology

89

Research Article

Trauma symptoms and their correlates among Zimbabwean adolescents: Baseline results from a cluster randomized controlled trial.

Zimbabwean Adolescents Report High Trauma Burden, With Girls and Low-Resilience Youth Most Affected — In a school-based sample of 1,342 Zimbabwean adolescents aged 12–18, youth endorsed an average of 7.6 out of 18 possible trauma symptoms, with girls reporting significantly more than boys (t[1325]=3.39, p=.0007), and trauma symptom severity was inversely correlated with self-esteem (r=-.36, p<.001), self-calming ability (r=-.30, p<.001), and social support (r=-.23, p<.001).

Sep 9, 2026 · PLOS Ment Health · Pediatrics

80

Clinical Trial

Improved quality of life and prolonged survival with add-on homeopathic treatment in patients with non-small cell lung cancer: a prospective, randomized, placebo-controlled, double-blind, three-arm, multicenter study.

Add-On Homeopathy Linked to Longer Survival and Better Quality of Life in Stage IV NSCLC — In a placebo-controlled trial of patients with stage IV non-small cell lung cancer, those receiving individualized homeopathic medicinal products alongside conventional treatment had a median survival of 435 days compared with 257 days in the placebo group — nearly 70% longer — and reported meaningfully better quality of life across most functional and symptom domains.

Sep 10, 2026 · Support Care Cancer · Oncology

83

Research Article

Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

Durvalumab Added to Perioperative FLOT Significantly Improves Overall Survival in Resectable Gastric Cancer — In a global phase 3 trial of 948 patients with resectable gastric or gastro-oesophageal junction adenocarcinoma, adding durvalumab to perioperative FLOT chemotherapy reduced the risk of death by approximately 22% compared with FLOT alone — about 22% lower risk of death (HR 0.78, 95% CI 0.63–0.96; p=0.021).

Sep 9, 2026 · Lancet · Oncology

92

Research Article

Effects of sodium reduction interventions on home and morning home blood pressure: a systematic review and meta-analysis of randomized controlled trials.

Sodium Reduction Lowers Home and Morning Blood Pressure, Most in Hypertensive Patients — A systematic review and meta-analysis of 23 randomized controlled trials found that sodium reduction interventions lowered home systolic blood pressure by approximately 3.66 mmHg (95% CI −4.86 to −2.45) and morning home systolic blood pressure by approximately 4.06 mmHg (95% CI −6.60 to −1.52), with meaningfully larger reductions in participants with established hypertension.

Sep 9, 2026 · Hypertens Res · Cardiology

82

Randomized Controlled Trial

[Tafluprost/timolol fixed-dose combination versus tafluprost monotherapy for open-angle glaucoma and ocular hypertension: a multicenter, randomized, double-blind, parallel-group trial].

Tafluprost/Timolol Fixed-Dose Combination Shows Superior IOP Reduction Over Tafluprost Alone — A preservative-free tafluprost/timolol fixed-dose combination reduced mean diurnal intraocular pressure significantly more than tafluprost monotherapy at three months, with a between-group difference of approximately 1.3 mmHg in favor of the combination (between-group difference: −1.312 mmHg, 95% CI: −2.010 to −0.696).

Sep 11, 2026 · Zhonghua Yan Ke Za Zhi · Cardiology

90

Research Article

Efficacy and Safety of Fixed-Dose Combination Therapy with Cilostazol and Rosuvastatin in Patients with Symptomatic Lower Extremity Peripheral Artery Disease: A Multicenter Randomized Controlled Trial.

Cilostazol Added to Rosuvastatin Significantly Improves Quality of Life in Symptomatic PAD — In a 24-week multicenter randomized controlled trial, patients with symptomatic peripheral artery disease who received cilostazol plus rosuvastatin showed a statistically significant 5.1-point greater improvement in patient-reported health status compared with rosuvastatin alone (95% CI 1.5–8.7; P = 0.005).

Sep 7, 2026 · Cardiovasc Drugs Ther · Cardiology

93